• Mashup Score: 0

    October 3, 2023 — A discovery of a mutation in the gene ACTA2 has given researchers, led by Dianna Milewicz, MD, PhD, with UTHealth Houston, insight into understanding the cause of a rare and progressive problem with arteries in the brain and a cause of strokes in young children, called moyamoya disease.  The findings were published today in Nature Cardiovascular Research.  Moyamoya disease is a condition where the arteries going through the neck and into the brain become blocked right when the arteries enter the brain. Moyamoya disease can lead to strokes and seizures. Children only a few months old can suffer a stroke due to the disease. Current treatments are limited to medications to reduce the risk of stroke and surgery to open or bypass blocked arteries.  “This disease is one of the major causes of stroke in children and nobody knows why this happens or why these arteries get clogged,” said Milewicz, senior author of the study and professor and director of the Division of Medical

    Tweet Tweets with this article
    • @DAICeditor @DiannaMilewicz @UTHealthHouston A discovery of a mutation in the gene #ACTA2 has given researchers insight into understanding the cause of a rare and progressive problem with #arteries in the brain and a cause of #strokes in young #children: https://t.co/ScCWxejCDG

  • Mashup Score: 0

    Racial and ethnic minority populations in the United States, especially Black children, endure an increased burden of asthma due to factors such as environmental exposure, access to health care, and genetics.1 Compared with White children, Black children with asthma experience reduced quality of life, have more poorly controlled disease, require longer-term corticosteroid use, and are more frequently evaluated in emergency department visits.1 In addition, Black children are 3 times as likely to be hospitalized and 7 times as likely to die from asthma as White children.

    Tweet Tweets with this article
    • In Current Issue! Similar #response to #omalizumab in #children with #allergic #asthma from different #racial #backgrounds https://t.co/62vGNMKQoJ https://t.co/zDVu39ioY6

  • Mashup Score: 1

    is condition. All members of the Nutrition Committee of the European Society for Paediatric Gastroenterology Hepatology and Nutrition (ESPGHAN) contributed to this position paper. Some renowned experts in the field joined the team to guide with their experience. A systematic literature search was performed from 2005 to May 2021 using PubMed, MEDLINE, and Cochrane Database of Systematic Reviews. In the absence of evidence, recommendations reflect the expert opinion of the authors. Literature on SBS mainly consists of retrospective single-center experience, thus most of the current papers and recommendations are based on expert opinion. All recommendations were voted on by the expert panel and reached >90% agreement. The first part of this position paper focuses on the physiological mechanism of intestinal adaptation after surgical resection. It subsequently provides some clinical practice recommendations for the primary management of children with SBS from surgical resection until disch

    Tweet Tweets with this article
    • Nutrition and intestinal rehabilitation in #children with #SBS In part 2, the @ESPGHANSociety Committee on Nutrition highlights long-term follow-up 🌟 How to monitor PN weaning and support adaptation by Norsa et al @lonorsa https://t.co/d7CVvuAN1w https://t.co/d7CVvuAN1w

  • Mashup Score: 3

    The availability of biologic agents for patients with severe asthma has increased dramatically over the last several decades. The absence of direct head-to-head comparative data and relative lack of biomarkers to predict response can make it difficult to choose the right biologic medication for a given patient. Selecting a biologic agent for the pediatric population presents further challenges due to more limited approved biologic agents and fewer clinical trials in children. In addition, the outcome data that are currently available suggest that treatment responses for a given biologic may be different between adult and pediatric patients.

    Tweet Tweets with this article
    • In Press! #Controversies in #Allergy: Are #Biologic #Treatment #Responses in #Severe #Asthma the Same in #Adults and #Children? https://t.co/zLhlpkLQgn https://t.co/MeP7VrK23L